RxDoctor Payments Data

Yochai Birnbaum, MD

Cardiovascular Disease · Houston, TXNPI 1114086931

Payments from drug & device makers

$21,598in general payments, 2019–2025

Across 27 payments — averaging $799.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$12K
  • Astrazeneca AB$7K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Abbott$1K
  • Pfizer$229
  • Abiomed$94
  • plus $78 from 3 others

What the payments were for

  • Consulting fees$20,02393%
  • Food & beverage$1,5767%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,598 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$119,022
Medicare patients
1,526
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$97,979
XareltoRivaroxaban44$57,780
FarxigaDapagliflozin Propanediol13$7,621
Candesartan Cilexetil22$2,337
Nifedipine ErNifedipine98$2,309
Atorvastatin Calcium269$2,306
Metoprolol Succinate99$2,090
Losartan Potassium147$1,657
Ezetimibe81$1,406
Rosuvastatin Calcium80$1,386
Amlodipine Besylate147$1,134
Bisoprolol Fumarate57$1,006
Lisinopril101$932
Hydralazine Hcl65$930
ClopidogrelClopidogrel Bisulfate69$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$229$97,97986 claims
AstraZenecaFarxiga$11,758$7,62113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →